
	<p>Aufmachungsvorschrift / Packaging Master Endoxan 50 mg 50 Dragees / Dragees Product No. 2638B1090 Export Spanisch (EPS)</p>	<p>LCCAV 17314d/08 Vertraulich Confidential</p>
---	---	--


Darstellung Mat.-Nr. / Illustration Mat.-No.: HA7101090 verwendet in / used in: 2638B1090

<p>Lot: Lot: Lot: Lot:</p>	<p>ENDOXAN 50 mg Ciclofosfamida 50 mg grageas via oral Reg. No.: CO INVIMA 2016M-008010-R3 RCH Reg ISP N° F-14350/14 YV Registrado; MPPS No EF.9937/11 Baxter Oncology GmbH</p>	<p>ENDOXAN 50 mg Ciclofosfamida 50 mg grageas via oral Reg. No.: CO INVIMA 2016M-008010-R3 RCH Reg ISP N° F-14350/14 YV Registrado; MPPS No EF.9937/11 Baxter Oncology GmbH</p>	<p>ENDOXAN 50 mg Ciclofosfamida 50 mg grageas via oral Reg. No.: CO INVIMA 2016M-008010-R3 RCH Reg ISP N° F-14350/14 YV Registrado; MPPS No EF.9937/11 Baxter Oncology GmbH EPS HA-71-01-090</p>	<p>M.M.A.A.A.A M.M.A.A.A.A M.M.A.A.A.A M.M.A.A.A.A</p>
	<p>AMXXX</p>			

Release Status : Issued and Effective

	<p>Aufmachungsvorschrift / Packaging Master Endoxan 50 mg 50 Dragees / Dragees Product No. 2638B1090 Export Spanisch (EPS)</p>	<p>LCCAV 17314d/08 Vertraulich Confidential</p>
---	---	--

Darstellung Mat.-Nr. / Illustration Mat.-No.: HA8002259 verwendet in / used in: 2638B1090



Release Status : Issued and Effective